GlassScriptPhysician profile
Charles R Klettner
NPI 1760441646
$1,430.07
in general payments reported to CMS, 2019-2025
27 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $105 · 2021: $198 · 2022: $198 · 2023: $320 · 2024: $234 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.46 | 2021-2025 | |
| Novo Nordisk INC | $208.92 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $125.94 | 2019-2023 | Veozah |
| Pfizer INC. | $114.08 | 2019-2025 | |
| Amgen INC. | $95.77 | 2019-2024 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $57.22 | 2021-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $54.45 | 2019-2023 | Gardasil 9, Vaxneuvance |
| Glaxosmithkline, LLC. | $52.29 | 2020-2022 | |
| Exact Sciences Corporation | $48.54 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $46.03 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.57 | 2019-2022 | |
| Horizon Therapeutics Plc | $37.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.66 | 2019-2023 | Spravato |
| Xeris Pharmaceuticals, INC. | $32.83 | 2023-2025 | Gvoke Hypopen |
| Amarin Pharma, INC. | $29.75 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.20 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.90 | 2024 | Rexulti |
| Corium, LLC | $21.53 | 2024 | Azstarys |
| Mylan Specialty L.P. | $17.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.55 | 2019 | |
| Daiichi Sankyo INC. | $17.04 | 2024 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $16.65 | 2021 | |
| Baxter Healthcare | $14.27 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Sanofi Pasteur INC. | $14.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.65 | 2024 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $13.37 | 2021 | |
| Therapeuticsmd, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Klettner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.